NICE has said Roche's Tecentriq (atezolizumab) should not get regular NHS funding in first draft guidance as a treatment for metastastic triple negative breast cancer (TNBC), saying that it
Merck & Co has unveiled data from its immunotherapy Keytruda that could allow it to gain a foothold in the tough-to-treat triple negative breast cancer (TNBC) indication, and potentiall